Zacks Research cut their Q2 2026 earnings estimates for shares of BioMarin Pharmaceutical in a research report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now expects that the ...

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

We recently published a list of Paul Singer’s Latest Portfolio: Top 10 Stock Picks. In this article, we are going to take a ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Selling resumed on Wall Street on Tuesday as investors monitored the broader market, which saw a noticeable decline ahead of the Federal Open Market Committee's upcoming rate decision. With the market ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or CSL Limited Sponsored ADR (CSLLY). But which of these two ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday. BMRN has ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

In a report released on March 14, Jessica Fye from J.P. Morgan maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...